Search
Bertilimumab
go.drugbank.com/drugs/DB05429InvestigationalIt is developed by MedImmune for the treatment of Allergic Rhinitis.
Equilenin
go.drugbank.com/drugs/DB03515ExperimentalEquilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.
PRGN-3006
go.drugbank.com/drugs/DB17229InvestigationalPRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface
Synonyms: Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surfaceCYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Fluocinonide
go.drugbank.com/drugs/DB01047ApprovedInvestigationalA topical glucocorticoid used in the treatment of eczema.
Ethionamide
go.drugbank.com/drugs/DB00609ApprovedInvestigationalWithdrawnA second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Brilliant green cation
go.drugbank.com/drugs/DB11279ApprovedVet approvedDue to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection. … Brilliant green, or ethanaminium, is a derivative of triarylmethane dye that has been used as a dye to color silk and wool.
FINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalFINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity
SCB-2019
go.drugbank.com/drugs/DB15805InvestigationalThe vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.